Caprock Group, Inc. Atai Life Sciences N.V. Transaction History
Caprock Group, Inc.
- $4.51 Billion
- Q4 2025
A detailed history of Caprock Group, Inc. transactions in Atai Life Sciences N.V. stock. As of the latest transaction made, Caprock Group, Inc. holds 52,075 shares of ATAI stock, worth $208,300. This represents 0.0% of its overall portfolio holdings.
Number of Shares
52,075Holding current value
$208,300% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding ATAI
# of Institutions
151Shares Held
38MCall Options Held
1.88MPut Options Held
543K-
Adage Capital Partners Gp, L.L.C. Boston, MA5.43MShares$21.7 Million0.05% of portfolio
-
Morgan Stanley New York, NY4.82MShares$19.3 Million0.0% of portfolio
-
Ken Griffin Citadel Advisors LLC | Chicago, Il2.58MShares$10.3 Million0.0% of portfolio
-
Ally Bridge Group (Ny) LLC New York, NY2.29MShares$9.15 Million12.47% of portfolio
-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl2.02MShares$8.08 Million0.07% of portfolio
About ATAI Life Sciences N.V.
- Ticker ATAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 165,875,008
- Market Cap $664M
- Description
- Atai Life Sciences N.V., through its subsidiary, ATAI Life Sciences AG, operates as a clinical-stage biopharmaceutical company. It engages in developing various therapeutic candidates that focuses on various mental health disorders. The company's therapeutic candidates include PCN-101, a subcutaneous formulation of R-ketamine for the treatment o...